Corcept Therapeutics (CORT) Change in Account Payables (2010 - 2026)

Corcept Therapeutics has disclosed Change in Account Payables across 17 years of filings, most recently posting -$7.6 million for Q1 2026.

• Change in Account Payables for Q1 2026 came in at -$7.6 million, down 160.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.9 million (down 68.51% YoY), and the FY2025 annual result was $25.1 million, up 1340.99% from the prior year.
• Change in Account Payables came in at -$7.6 million for Q1 2026 at Corcept Therapeutics, down from $6.0 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $12.6 million in Q1 2025 to a low of -$7.6 million in Q1 2026.
• The 5-year median for Change in Account Payables is -$165000.0 (2022), against an average of $1.5 million.
• Across the five-year window, Change in Account Payables jumped 5303.03% in 2023 and slumped 649.0% in 2024, its largest moves.
• Corcept Therapeutics' Change in Account Payables stood at $4.2 million in 2022, then tumbled by 84.98% to $637000.0 in 2023, then plunged by 587.6% to -$3.1 million in 2024, then surged by 293.11% to $6.0 million in 2025, then plunged by 227.44% to -$7.6 million in 2026.
• The last three Change in Account Payables figures came in at -$7.6 million (Q1 2026), $6.0 million (Q4 2025), and $10.9 million (Q3 2025), per Business Quant data.